OncoVent Co., Ltd., a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., entered into a license agreement with Orient EuroPharma Co., Ltd. (OEP) granting OEP exclusive rights to the commercialization of oregovomab, an immunotherapy drug candidate, in Taiwan, including related regulatory applications and necessary clinical trials. OncoVent is entitled to a number of payments from OEP under the license agreement, including an upfront payment, multiple regulatory...